{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:59:35Z","timestamp":1777273175017,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,26]]},"DOI":"10.7759\/cureus.107772","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:28:56Z","timestamp":1777271336000},"source":"Crossref","is-referenced-by-count":0,"title":["Expert Opinion on Optimising Guideline-Directed Medical Therapy and Expanding the Role of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) for Heart Failure Management in India"],"prefix":"10.7759","author":[{"given":"Bijay Prakash","family":"Pandey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumitra","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumitra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santanu","family":"Guha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhupen  N","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh K","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Kudva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Kumar","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrashekhar K","family":"Ponde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjan Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipak","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurunath","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Kolapkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen A","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020, 22:1342-56. 10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger VL","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021, 128:1421-34. 10.1161\/CIRCRESAHA.121.318172","journal-title":"Circ Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.03","article-title":"Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction","volume":"9","author":"Kapelios CJ","year":"2023","unstructured":"Kapelios CJ, Shahim B, Lund LH, Savarese G. Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card Fail Rev. 2023, 9:e14. 10.15420\/cfr.2023.03","journal-title":"Card Fail Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5152\/akd.2014.5731","article-title":"Mortality in heart failure patients","volume":"15","author":"Byty\u00e7i I","year":"2015","unstructured":"Byty\u00e7i I, Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol. 2015, 15:63-8. 10.5152\/akd.2014.5731","journal-title":"Anatol J Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.10.012","article-title":"Five-year mortality and readmission rates in patients with heart failure in India: results from the Trivandrum heart failure registry","volume":"326","author":"Harikrishnan S","year":"2021","unstructured":"Harikrishnan S, Jeemon P, Ganapathi S, et al.. Five-year mortality and readmission rates in patients with heart failure in India: results from the Trivandrum heart failure registry. Int J Cardiol. 2021, 326:139-43. 10.1016\/j.ijcard.2020.10.012","journal-title":"Int J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab793","article-title":"The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy","volume":"43","author":"Joseph S","year":"2022","unstructured":"Joseph S, Panniyammakal J, Abdullakutty J, et al.. The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy. Eur Heart J. 2022, 43:908-15. 10.1093\/eurheartj\/ehab793","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.03.430","article-title":"Implementing guideline-directed medical therapy for heart failure: JACC focus seminar 1\/3","volume":"82","author":"Patolia H","year":"2023","unstructured":"Patolia H, Khan MS, Fonarow GC, Butler J, Greene SJ. Implementing guideline-directed medical therapy for heart failure: JACC focus seminar 1\/3. J Am Coll Cardiol. 2023, 82:529-43. 10.1016\/j.jacc.2023.03.430","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene SJ","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, et al.. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018, 72:351-66. 10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1101\/2023.09.08.23295280","article-title":"Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021-2022: an analysis of real-world data [PREPRINT]","volume":"0","author":"Alonso A","year":"2023","unstructured":"Alonso A, Morris AA, Naimi AI, et al.. Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021-2022: an analysis of real-world data [PREPRINT]. medRxiv. 2023, 0:0. 10.1101\/2023.09.08.23295280","journal-title":"medRxiv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14096","article-title":"Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry","volume":"9","author":"Harikrishnan S","year":"2022","unstructured":"Harikrishnan S, Bahl A, Roy A, et al.. Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry. ESC Heart Fail. 2022, 9:3898-908. 10.1002\/ehf2.14096","journal-title":"ESC Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer M","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, et al.. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002, 106:2194-9. 10.1161\/01.cir.0000035653.72855.bf","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf S","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325:293-302. 10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger CB","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al.. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003, 362:772-6. 10.1016\/S0140-6736(03)14284-5","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999, 353:2001-7. 10.1016\/S0140-6736(99)04440-2","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow MR","year":"1996","unstructured":"Bristow MR, Gilbert EM, Abraham WT, et al.. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996, 94:2807-16. 10.1161\/01.cir.94.11.2807","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad F","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al.. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364:11-21. 10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa A","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, et al.. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022, 400:1938-52. 10.1016\/S0140-6736(22)02076-1","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad F","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al.. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet. 2020, 396:819-29. 10.1016\/S0140-6736(20)31824-9","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac210","article-title":"Accelerated and personalized therapy for heart failure with reduced ejection fraction","volume":"43","author":"Shen L","year":"2022","unstructured":"Shen L, Jhund PS, Docherty KF, et al.. Accelerated and personalized therapy for heart failure with reduced ejection fraction. Eur Heart J. 2022, 43:2573-87. 10.1093\/eurheartj\/ehac210","journal-title":"Eur Heart J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer M","year":"2021","unstructured":"Packer M, McMurray JJ. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail. 2021, 23:882-94. 10.1002\/ejhf.2149","journal-title":"Eur J Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Brunner-La Rocca HP","year":"2019","unstructured":"Brunner-La Rocca HP, Linssen GC, Smeele FJ, et al.. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry. JACC Heart Fail. 2019, 7:13-21. 10.1016\/j.jchf.2018.10.010","journal-title":"JACC Heart Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng TK","year":"2018","unstructured":"Teng TK, Tromp J, Tay WT, et al.. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018, 6:e1008-18. 10.1016\/S2214-109X(18)30306-1","journal-title":"Lancet Glob Health"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro MG","year":"2016","unstructured":"Crespo-Leiro MG, Anker SD, Maggioni AP, et al.. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016, 18:613-25. 10.1002\/ejhf.566","journal-title":"Eur J Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.510","article-title":"Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda M","year":"2016","unstructured":"Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi L. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016, 18:514-22. 10.1002\/ejhf.510","journal-title":"Eur J Heart Fail"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese G","year":"2021","unstructured":"Savarese G, Bodegard J, Norhammar A, et al.. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail. 2021, 23:1499-511. 10.1002\/ejhf.2271","journal-title":"Eur J Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.20","article-title":"Initiation and up-titration of guideline-directed medical therapy for patients with heart failure: better, faster, stronger!","volume":"10","author":"Carrizales-Sep\u00falveda EF","year":"2024","unstructured":"Carrizales-Sep\u00falveda EF, Ordaz-Far\u00edas A, Vargas-Mendoza JA, Vera-Pineda R, Flores-Ram\u00edrez R. Initiation and up-titration of guideline-directed medical therapy for patients with heart failure: better, faster, stronger!. Card Fail Rev. 2024, 10:e03. 10.15420\/cfr.2023.20","journal-title":"Card Fail Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.838","article-title":"The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets","volume":"19","author":"Zaman S","year":"2017","unstructured":"Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP, Cole GD. The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail. 2017, 19:1401-9. 10.1002\/ejhf.838","journal-title":"Eur J Heart Fail"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.10.005","article-title":"How to initiate and uptitrate GDMT in heart failure: practical stepwise approach to optimization of GDMT","volume":"10","author":"Bozkurt B","year":"2022","unstructured":"Bozkurt B. How to initiate and uptitrate GDMT in heart failure: practical stepwise approach to optimization of GDMT. JACC Heart Fail. 2022, 10:992-5. 10.1016\/j.jchf.2022.10.005","journal-title":"JACC Heart Fail"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00646-4","article-title":"Advancing guideline-directed medical therapy in heart failure: overcoming challenges and maximizing benefits","volume":"24","author":"Zhang Z","year":"2024","unstructured":"Zhang Z, Wang C, Tu T, et al.. Advancing guideline-directed medical therapy in heart failure: overcoming challenges and maximizing benefits. Am J Cardiovasc Drugs. 2024, 24:329-42. 10.1007\/s40256-024-00646-4","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-023-00323-8","article-title":"Practical recommendations for the use of angiotensin receptor-neprilysin inhibitors (ARNI) in heart failure: insights from Indian cardiologists","volume":"12","author":"Dalal J","year":"2023","unstructured":"Dalal J, Chandra P, Ray S, et al.. Practical recommendations for the use of angiotensin receptor-neprilysin inhibitors (ARNI) in heart failure: insights from Indian cardiologists. Cardiol Ther. 2023, 12:445-71. 10.1007\/s40119-023-00323-8","journal-title":"Cardiol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-024-00367-4","article-title":"Management of heart failure in a resource-limited setting: expert opinion from India","volume":"13","author":"Jain P","year":"2024","unstructured":"Jain P, Guha S, Kumar S, et al.. Management of heart failure in a resource-limited setting: expert opinion from India. Cardiol Ther. 2024, 13:243-66. 10.1007\/s40119-024-00367-4","journal-title":"Cardiol Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy CW","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017, 70:776-803. 10.1016\/j.jacc.2017.04.025","journal-title":"J Am Coll Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.11648\/j.ajim.20180604.11","article-title":"Valsartan\/sacubitril for treatment of HFrEF: a single center\u2019s paradigm","volume":"6","author":"Morris KL","year":"2018","unstructured":"Morris KL, Shmukler E, Schmit A, et al.. Valsartan\/sacubitril for treatment of HFrEF: a single center\u2019s paradigm. Am J Intern Med. 2018, 6:52-5. 10.11648\/j.ajim.20180604.11","journal-title":"Am J Intern Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1159\/000545195","article-title":"Sacubitril-valsartan lowers blood pressure in patients on dialysis: a randomized controlled multicenter study","volume":"11","author":"Lin L","year":"2025","unstructured":"Lin L, Bian W, Luo Q, et al.. Sacubitril-valsartan lowers blood pressure in patients on dialysis: a randomized controlled multicenter study. Kidney Dis (Basel). 2025, 11:206-17. 10.1159\/000545195","journal-title":"Kidney Dis (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan M","year":"2023","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL, et al.. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023, 44:2982-93. 10.1093\/eurheartj\/ehad344","journal-title":"Eur Heart J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13705","article-title":"Eligibility of patients with heart failure with preserved ejection fraction for sacubitril\/valsartan according to the PARAGON-HF trial","volume":"9","author":"Lund LH","year":"2022","unstructured":"Lund LH, Savarese G, Venkateshvaran A, et al.. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril\/valsartan according to the PARAGON-HF trial. ESC Heart Fail. 2022, 9:164-77. 10.1002\/ehf2.13705","journal-title":"ESC Heart Fail"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox TM","year":"2024","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al.. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024, 83:1444-88. 10.1016\/j.jacc.2023.12.024","journal-title":"J Am Coll Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046634","article-title":"Efficacy of neprilysin inhibition in women with HFpEF: beyond phenotypes and natriuretic peptides","volume":"143","author":"Cooper LB","year":"2021","unstructured":"Cooper LB, Cotugno A, deFilippi C. Efficacy of neprilysin inhibition in women with HFpEF: beyond phenotypes and natriuretic peptides. Circulation. 2021, 143:618-20. 10.1161\/CIRCULATIONAHA.120.046634","journal-title":"Circulation"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.4103\/heartindia.heartindia_95_21","article-title":"Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction - \"ARNI-PRESERVED\" study","volume":"9","author":"Jariwala P","year":"2021","unstructured":"Jariwala P, Punjani A, Boorugu H, Madhawar DB, Jadhav K. Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction - \"ARNI-PRESERVED\" study. Heart India. 2021, 9:179-83. 10.4103\/heartindia.heartindia_95_21","journal-title":"Heart India"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1177\/26324636241234159","article-title":"Effectiveness and safety of sacubitril\/valsartan in heart failure in India: a retrospective real-world (SAVE) study","volume":"5","author":"Sachdeva A","year":"2024","unstructured":"Sachdeva A, Shukla A, Mayabhate M, Kapure N. Effectiveness and safety of sacubitril\/valsartan in heart failure in India: a retrospective real-world (SAVE) study. Indian J Clin Cardiol. 2024, 5:191-5. 10.1177\/26324636241234159","journal-title":"Indian J Clin Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2025.05.094","article-title":"iCARDIO Alliance global implementation guidelines on heart failure 2025","volume":"34","author":"Chopra V","year":"2025","unstructured":"Chopra V, Khan MS, Abdelhamid M, et al.. iCARDIO Alliance global implementation guidelines on heart failure 2025. Heart Lung Circ. 2025, 34:e55-82. 10.1016\/j.hlc.2025.05.094","journal-title":"Heart Lung Circ"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.035","article-title":"Sacubitril\/valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction","volume":"83","author":"Fo\u00e0 A","year":"2024","unstructured":"Fo\u00e0 A, Vaduganathan M, Claggett BL, et al.. Sacubitril\/valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction. J Am Coll Cardiol. 2024, 83:1731-9. 10.1016\/j.jacc.2024.02.035","journal-title":"J Am Coll Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061572","article-title":"The efficacy and safety of sacubitril\/valsartan compared to valsartan in patients with heart failure and mildly reduced and preserved ejection fractions: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Kommu S","year":"2024","unstructured":"Kommu S, Berg RL. The efficacy and safety of sacubitril\/valsartan compared to valsartan in patients with heart failure and mildly reduced and preserved ejection fractions: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2024, 13:1572. 10.3390\/jcm13061572","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3259.ijct20241617","article-title":"Assessing hypotension incidence and dosing strategies of sacubitril\/valsartan in real-world heart failure management: protocol for a retrospective, multicentre and cohort study","volume":"11","author":"Jadhav UM","year":"2024","unstructured":"Jadhav UM, Shah J, Mohanty A, et al.. Assessing hypotension incidence and dosing strategies of sacubitril\/valsartan in real-world heart failure management: protocol for a retrospective, multicentre and cohort study. Int J Clin Trials. 2024, 11:215-9. 10.18203\/2349-3259.ijct20241617","journal-title":"Int J Clin Trials"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.11.059","article-title":"Improving guideline-directed medical therapy (GDMT) adherence in heart failure: results from a multicenter intervention study in India","volume":"32","author":"Singh H","year":"2026","unstructured":"Singh H, Singh S, Beri A, et al.. Improving guideline-directed medical therapy (GDMT) adherence in heart failure: results from a multicenter intervention study in India. J Card Fail. 2026, 32:196-7. 10.1016\/j.cardfail.2025.11.059","journal-title":"J Card Fail"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-025-10481-7","article-title":"Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum","volume":"30","author":"Shahid I","year":"2025","unstructured":"Shahid I, Khan MS, Butler J, Fonarow GC, Greene SJ. Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum. Heart Fail Rev. 2025, 30:515-23. 10.1007\/s10741-025-10481-7","journal-title":"Heart Fail Rev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.03.001","article-title":"Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure","volume":"12","author":"Greene SJ","year":"2024","unstructured":"Greene SJ, Ayodele I, Pierce JB, et al.. Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure. JACC Heart Fail. 2024, 12:1365-77. 10.1016\/j.jchf.2024.03.001","journal-title":"JACC Heart Fail"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03628-4","article-title":"Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial","volume":"31","author":"Herrmann JJ","year":"2025","unstructured":"Herrmann JJ, Brunner-La Rocca HP, Baltussen LE, et al.. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med. 2025, 31:2062-8. 10.1038\/s41591-025-03628-4","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.05.014","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status","volume":"11","author":"Peikert A","year":"2023","unstructured":"Peikert A, Goyal P, Vaduganathan M, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status. JACC Heart Fail. 2023, 11:1380-93. 10.1016\/j.jchf.2023.05.014","journal-title":"JACC Heart Fail"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.06.018","article-title":"Sacubitril\/valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction","volume":"9","author":"Carnicelli AP","year":"2021","unstructured":"Carnicelli AP, Li Z, Greiner MA, et al.. Sacubitril\/valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction. JACC Heart Fail. 2021, 9:876-86. 10.1016\/j.jchf.2021.06.018","journal-title":"JACC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453089-expert-opinion-on-optimising-guideline-directed-medical-therapy-and-expanding-the-role-of-angiotensin-receptor-neprilysin-inhibitors-arnis-for-heart-failure-management-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:28:57Z","timestamp":1777271337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453089-expert-opinion-on-optimising-guideline-directed-medical-therapy-and-expanding-the-role-of-angiotensin-receptor-neprilysin-inhibitors-arnis-for-heart-failure-management-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7759\/cureus.107772","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,26]]}}}